Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center

Articles

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

July 26th 2023

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

July 19th 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

July 19th 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Assessing HER2 Expression in Metastatic Colorectal Cancer

July 12th 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer

July 12th 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Colorectal Cancer: Evolving Role of ctDNA Testing in Practice

June 28th 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer

June 21st 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Biomarker Testing in Metastatic Colorectal Cancer

June 21st 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Colorectal Cancer: An Overview on Molecular Profiling

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

Exciting Treatment Opportunities in mCRC

May 28th 2021

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Decisions for Sequencing Therapy for HER2-Expressing mCRC

May 28th 2021

Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.

Novel Therapies for HER2-Expressing mCRC

May 28th 2021

Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.

Novel Combinations Being Investigated for mCRC Treatment

May 21st 2021

Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.

Dual I-O Therapy for mCRC

May 21st 2021

Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.

Best Practices Surrounding IO Treatment for mCRC

May 14th 2021

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Frontline I-O Treatment for mCRC

May 14th 2021

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.